NCM
CDTX

Nantahala Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Nantahala Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-77,337
Closed -$1.23M – 126
2023
Q4 		$1.23M Sell
77,337
-49,583
-39% -$796K 0.12% 104
2023
Q3 		$2.39M Sell
126,920
-71,175
-36% -$1.4M 0.3% 84
2023
Q2 		$4.48M Sell
198,095
-38,387
-16% -$902K 0.54% 51
2023
Q1 		$6.01M Buy
236,482
+18,109
+8% +$514K 0.58% 45
2022
Q4 		$3.3M Sell
218,373
-9,587
-4% -$114K 0.3% 64
2022
Q3 		$2.92M Sell
227,960
-12,995
-5% -$179K 0.29% 64
2022
Q2 		$2.35M Sell
240,955
-6,789
-3% -$83.9K 0.2% 80
2022
Q1 		$4.13M Sell
247,744
-15,779
-6% -$268K 0.29% 67
2021
Q4 		$6.69M Buy
+263,523
New +$8.2M 0.42% 73

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $186M AUM 51.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $57.5B AUM 55.25% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $12.3B AUM 37.17% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return